Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services

TOKYO, June 6, 2023 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) announces that it will launch a commercial office^*1 in Tokyo to provide enhanced sales support and customer service for Contract Development and Manufacturing services for Biologics and Advanced Therapies to Asia-based pharmaceutical and biotechnology companies. Scheduled to open in July 2023, the new regional commercial office located in Minato, Tokyo, will be part of FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO).

FUJIFILM Diosynth Biotechnologies provides contract services for process development, small-to-large-scale manufacturing of drug substances and drug products for a variety of therapeutic modalities including monoclonal antibodies, cell and gene therapies, and vaccines. Process development and contract services are offered at FUJIFILM Diosynth Biotechnologies’ six world-class development and manufacturing campuses across the U.S. and Europe.

The global market of biologic-based therapeutics is expected to grow steadily, which is attributed to the increasing demand for monoclonal antibodies and gene therapies. Asia has seen an increasing number of clinical pipelines at a rate of more than 9% in the past 10 years^*2, fueled by strong research and development efforts. This growth trend is expected to continue in the region with an estimated 1,900 new products^*3 currently in clinical development.

“Fujifilm continues to expand its global footprint to support our customers locally,” said Takatoshi Ishikawa, general manager at the Bio CDMO division, FUJIFILM Corporation. “We look forward to supporting the development of life-impacting new therapies for patients and their families.”

Fujifilm continues to expand its Bio CDMO business through its integrated business operations across the U.S., Europe, and Asia. Underpinned by ongoing strategic initiatives including capital investment into its manufacturing facilities and taking 100% capital ownership of its subsidiaries^*4, the company plans to achieve the revenue growth of more than 20% in 12 years from the fiscal year ended March 2019 to the fiscal year ending March 2031, which is above the overall market CAGR of 13%^*5.

^{**1           FUJIFILM Diosynth Biotechnologies Japan Corporation, a 100% subsidiary registered company registered as of June 2, 2023 under the Japanese laws and regulations.}

^{**2           Based on Fujifilm research combined with data from Global Trend in R&D 2023, IQVIA, Feb 2023.}

^{**3           Global Data Intelligence Center, extracted May 11, 2023.}

^{**4　　　 FUJIFILM Diosynth Biotechnologies U.S.A., Inc., FUJFIILM Diosynth Biotechnologies UK Limited, and FUJFIILM 　Diosynth Biotechnologies Texas LLC. The timing of taking 100% capital ownership is planned to be around July 2023, subject to the satisfaction of customary closing conditions.}

^{**5           Based on Fujifilm research.}

For inquiries on information in this media release, contact:

Media contact:

FUJIFILM Holdings Corporation

Corporate Communications Division, Public Relations Group  TEL: +81-3-6271-2000

Other Contact:

FUJIFILM Corporation Bio CDMO Division　TEL: +81-3-6271-3025